Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple ...

Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide - - In a pivotal PPMS study ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUSTM ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory small molecule therapy that can cross the blood-brain barrier may be attractive ...

Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayed In response to an FDA request, Sanofi has submitted an ...

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis - The first (FENhance ...

ETHealthworld.com brings latest multiple sclerosis news, views and updates from all top sources for the Indian Health industry.

Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing secondary ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a ...